Literature DB >> 19741598

PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.

O Akbari1, P Stock, A K Singh, V Lombardi, W-L Lee, G J Freeman, A H Sharpe, D T Umetsu, R H Dekruyff.   

Abstract

Interactions of the inhibitory receptor programmed death-1 (PD-1) with its ligands, programmed death ligand (PD-L)1 and PD-L2, regulate T-cell activation and tolerance. In this study, we investigated the role of PD-L1 and PD-L2 in regulating invariant natural killer T (iNKT)-cell-mediated airway hyperreactivity (AHR) in a murine model of asthma. We found that the severity of AHR and airway inflammation is significantly greater in PD-L2(-/-) mice compared with wild-type mice after either ovalbumin (OVA) sensitization and challenge or administration of alpha-galactosylceramide (alpha-GalCer). iNKT cells from PD-L2(-/-) mice produced significantly more interleukin (IL)-4 than iNKT cells from control mice. Moreover, blockade of PD-L2 interactions of wild-type iNKT cells in vitro with monoclonal antibodies (mAbs) resulted in significantly enhanced levels of IL-4 production. In contrast, PD-L1(-/-) mice showed significantly reduced AHR and enhanced production of interferon-gamma (IFN-gamma) by iNKT cells. iNKT-deficient Jalpha18(-/-) mice reconstituted with iNKT cells from PD-L2(-/-) mice developed high levels of AHR, whereas mice reconstituted with iNKT cells from PD-L1(-/-) mice developed lower levels of AHR compared with control. As PD-L2 is not expressed on iNKT cells but rather is expressed on lung dendritic cells (DCs), in which its expression is upregulated by allergen challenge or IL-4, these findings suggest an important role of PD-L2 on lung DCs in modulating asthma pathogenesis. These studies also indicate that PD-L1 and PD-L2 have important but opposing roles in the regulation of AHR and iNKT-cell-mediated activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19741598      PMCID: PMC2845714          DOI: 10.1038/mi.2009.112

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  49 in total

1.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

Review 2.  CD1-restricted T-cell responses and microbial infection.

Authors:  S H Park; A Bendelac
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

Review 3.  The regulatory role of Valpha14 NKT cells in innate and acquired immune response.

Authors:  Masaru Taniguchi; Michishige Harada; Satoshi Kojo; Toshinori Nakayama; Hiroshi Wakao
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

4.  Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen.

Authors:  O Akbari; R H DeKruyff; D T Umetsu
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

5.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors:  Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

6.  Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways.

Authors:  Y Hayakawa; K Takeda; H Yagita; L Van Kaer; I Saiki; K Okumura
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

Review 7.  Natural killer T cells and the regulation of asthma.

Authors:  P Matangkasombut; M Pichavant; R H Dekruyff; D T Umetsu
Journal:  Mucosal Immunol       Date:  2009-07-08       Impact factor: 7.313

8.  Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

Authors:  Shin-ichiro Fujii; Kanako Shimizu; Mitchell Kronenberg; Ralph M Steinman
Journal:  Nat Immunol       Date:  2002-08-05       Impact factor: 25.606

9.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.

Authors:  S Y Tseng; M Otsuji; K Gorski; X Huang; J E Slansky; S I Pai; A Shalabi; T Shin; D M Pardoll; H Tsuchiya
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

View more
  73 in total

Review 1.  Turned on by danger: activation of CD1d-restricted invariant natural killer T cells.

Authors:  Victoria Lawson
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

Review 2.  Role of PD-L1 and PD-L2 in allergic diseases and asthma.

Authors:  A K Singh; P Stock; O Akbari
Journal:  Allergy       Date:  2010-08-17       Impact factor: 13.146

Review 3.  Atezolizumab for the treatment of non-small cell lung cancer.

Authors:  Fernando C Santini; Charles M Rudin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-07-27       Impact factor: 5.045

4.  Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10.

Authors:  Marta Rodríguez-García; Filippos Porichis; Olivier G de Jong; Karen Levi; Thomas J Diefenbach; Jeffrey D Lifson; Gordon J Freeman; Bruce D Walker; Daniel E Kaufmann; Daniel G Kavanagh
Journal:  J Leukoc Biol       Date:  2010-11-19       Impact factor: 4.962

Review 5.  Clinical view on the importance of dendritic cells in asthma.

Authors:  Rohit Gaurav; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2013-10       Impact factor: 4.473

Review 6.  Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.

Authors:  David F Heigener; Martin Reck
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

7.  Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.

Authors:  Rimas V Lukas; Jordi Rodon; Kevin Becker; Eric T Wong; Kent Shih; Mehdi Touat; Marcella Fassò; Stuart Osborne; Luciana Molinero; Carol O'Hear; William Grossman; Joachim Baehring
Journal:  J Neurooncol       Date:  2018-08-02       Impact factor: 4.130

8.  A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity.

Authors:  Vincent Lombardi; Philippe Stock; Abinav K Singh; Jerome Kerzerho; Wen Yang; Barbara A Sullivan; Xiangming Li; Takayuki Shiratsuchi; Nathan E Hnatiuk; Amy R Howell; Karl O A Yu; Steven A Porcelli; Moriya Tsuji; Mitchell Kronenberg; S Brian Wilson; Omid Akbari
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

9.  Blockade of RGMb inhibits allergen-induced airways disease.

Authors:  Sanhong Yu; Krystle M Leung; Hye-Young Kim; Sarah E Umetsu; Yanping Xiao; Lee A Albacker; Hyun-Jun Lee; Dale T Umetsu; Gordon J Freeman; Rosemarie H DeKruyff
Journal:  J Allergy Clin Immunol       Date:  2019-01-29       Impact factor: 10.793

10.  Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell.

Authors:  Hiroyasu Ito; Mitsuru Seishima
Journal:  J Biomed Biotechnol       Date:  2010-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.